source
- FDA issues third warning letter to Empower Pharmacy over GLP-1 weight-loss treatmentsThe U.S. Food and Drug Administration sent a formal warning letter to Empower Pharmacy, a compounder based in Houston, concerning its GLP-1 weight-loss products. The notice marks the company's thi…
- Trump Medicaid pricing plan may give Novo Nordisk unexpected financial boostSTAT reports that the White House introduced a plan aimed at lowering the cost of drugs for Medicaid beneficiaries. The policy includes provisions that reduce prices of obesity treatments for senio…